beta-Lapachone, Topoisomerase I inhibitor (ab141097)
Key features and details
- Topoisomerase I inhibitor
- CAS Number: 4707-32-8
- Purity: > 98%
- Soluble in ethanol to 50 mM and in DMSO to 100 mM
- Form / State: Solid
- Source: Synthetic
製品の概要
-
製品名
beta-Lapachone, Topoisomerase I inhibitor -
製品の詳細
Topoisomerase I inhibitor -
生理活性の詳細
Topoisomerase I inhibitor. Inhibits topoisomerase I induced DNA cleavage. Induces apoptosis via a p53 independent mechanism. Shows antitumor, antiviral, antibacterial, antifungal and wound healing activities.
-
精製度
> 98% -
CAS 番号
4707-32-8 -
構造式
製品の特性
-
体系名
3,4-Dihydro-2,2-dimethyl-2H-naphtho[1,2-b]pyran-5,6-dione -
分子量
242.27 -
分子式
C15H14O3 -
PubChem 登録番号
497540 -
保存方法
Store at +4°C. The product can be stored for up to 12 months. -
溶解性
Soluble in ethanol to 50 mM and in DMSO to 100 mM -
使用に関する注意
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES 線形表記
O=C3C(=O)c1ccccc1C2OC(C)(C)CCC23 -
由来
Synthetic
-
研究分野
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab141097の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
| アプリケーション | Abreviews | 特記事項 |
|---|---|---|
| Functional Studies |
Use at an assay dependent concentration.
|
| 特記事項 |
|---|
|
Functional Studies
Use at an assay dependent concentration. |
画像
-
Chemical Structure - beta-Lapachone, Topoisomerase I inhibitor (ab141097)
2D chemical structure of ab141097, beta-Lapachone, Topoisomerase I inhibitor
-
Functional Studies - beta-Lapachone, Topoisomerase I inhibitor (ab141097)ab18209 staining p21 in serum starved PC-3 cells treated with ß-lapachone (ab141097), by ICC/IF. Increase of p21 nuclear expression correlates with increased concentration of ß-lapachone, as described in literature.
The cells were incubated at 37°C for 6 hours in media containing different concentrations of ab141097 (ß-lapachone) in DMSO, fixed with 100% methanol for 5 minutes at -20°C and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab18209 (5 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.
プロトコール
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
参考文献 (4)
ab141097 は 4 報の論文で使用されています。
- Watermann P & Dringen R β-lapachone-mediated WST1 Reduction as Indicator for the Cytosolic Redox Metabolism of Cultured Primary Astrocytes. Neurochem Res 48:2148-2160 (2023). PubMed: 36811754
- Watermann P et al. G6PDi-1 is a Potent Inhibitor of G6PDH and of Pentose Phosphate pathway-dependent Metabolic Processes in Cultured Primary Astrocytes. Neurochem Res 48:3177-3189 (2023). PubMed: 37394677
- Steinmeier J et al. ß-Lapachone Induces Acute Oxidative Stress in Rat Primary Astrocyte Cultures that is Terminated by the NQO1-Inhibitor Dicoumarol. Neurochem Res 45:2442-2455 (2020). PubMed: 32789798
- Mokarizadeh N et al. ß-Lapachone attenuates cognitive impairment and neuroinflammation in beta-amyloid induced mouse model of Alzheimer's disease. Int Immunopharmacol 81:106300 (2020). PubMed: 32070922
